OBJECTIVE	To evaluate the efficacy of tolterodine extended-release ( ER ) plus tamsulosin on lower urinary tract symptoms ( LUTS ) as assessed by changes in the International Prostate Symptom Score ( IPSS ) in men who met symptom entry criteria for both overactive bladder ( OAB ) and benign prostatic hyperplasia ( BPH ) trials .\